前列腺癌与前列腺增生Ki-67/PCNA mRNA特异性表达比值的研究

Ratio of Ki-67/PCNA mRNA and its application in the diagnosis of BHP and prostate cancer

目的以实时荧光定量RT-PCR技术研究良性前列腺增生(BPH)与前列腺癌(PCa)组织标本Ki-67蛋白和组织核增殖抗原(PCNA)mRNA的比值,探讨此比值在PCa诊断中的特异性意义。方法通过实时荧光定量RT-PCR检测63例PCa和37例BPH前列腺组织Ki-67/PCNAmRNA的表达,比较其在PCa与BPH组织中定量的差异。结果BPH与PCa组织Ki-67/PC-NA mRNA的定量表达值分别为2.264±0.460与5.905±0.780,差异有统计学意义(P<0.05)。结论实时荧光定量RT-PCR检测Ki-67/PCNA mRNA为PCa的诊断提供了可靠的辅助指标。

Objective To study the ratio of Ki-67/PCNA mRNA and explore its application in the diagnosis of BPH and PCa. Methods A sensitive, real-time quantitative PCR assay was used to compare the expression difference of Ki-67/PCNA mRNA in BPH, PCa prostate tissue. Totally 63 samples of PCa and 37 BHP were studied. Results The ratio of Ki-67/PCNA mRNA in BPH and PCa prostate tissue is 2. 264±0. 460 and 5. 905±0. 780 respectively （P〈0. 05）. Conclusions The detection result of Ki-67/PCNA mRNA expression by QRT-PCR may provide reliable diagnostic information for differential diagnosis of PCa.